Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a...
Takeda
Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...
MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the Japanese Ministry of Health,...
Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China
Takeda Pharmaceutical Company Limited China (TYO: 4502; NYSE: TAK) entered into a partnership agreement with...
Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...
Takeda Reports Q1 FY2026 Revenue of JPY 1.22 Trillion, Outlines Growth Strategy Centered on Three Key Pipeline Assets
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) released its financial results for the first...
Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) and the Indonesian Government announced a groundbreaking...
Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets
Insilico Medicine (HKG: 3696) announced a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TYO:...
Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase...
Takeda’s Entyvio Receives FDA Acceptance for Pediatric sBLA in Ulcerative Colitis and Crohn’s Disease, Expanding Gut-Selective Biologic to Patients Aged 2+
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...
Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
A federal jury in the U.S. District Court for the District of Massachusetts returned a...
Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration...
Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported positive top-line results from two pivotal...
Belief BioMed Secures Macao Approval for BBM‑H901 – China’s First Hemophilia B Gene Therapy Expands to Greater China with Takeda
Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region...
Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36
Samsung Bioepis Co., Ltd. has expanded its strategic partnership with Sandoz AG (SWX: SDZ), entering...
Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA)...
Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) has entered a multi-year strategic agreement with Iambic Therapeutics,...